| Literature DB >> 27622336 |
Zhong-Qiang Guo1, Tong Zheng2, Baoen Chen3, Cheng Luo4, Sisheng Ouyang4, Shouzhe Gong3, Jiafei Li3, Liu-Liang Mao5, Fulin Lian6, Yong Yang7, Yue Huang2, Li Li3, Jing Lu8, Bidong Zhang9, Luming Zhou10, Hong Ding4, Zhiwei Gao7, Liqun Zhou11, Guoqiang Li12, Ran Zhou4, Ke Chen12, Jingqiu Liu4, Yi Wen6, Likun Gong8, Yuwen Ke12, Shang-Dong Yang5, Xiao-Bo Qiu10, Naixia Zhang6, Jin Ren8, Dafang Zhong7, Cai-Guang Yang13, Jiang Liu14, Hualiang Jiang15.
Abstract
In the cytoplasm of virtually all clear-cell renal cell carcinoma (ccRCC), speckle-type POZ protein (SPOP) is overexpressed and misallocated, which may induce proliferation and promote kidney tumorigenesis. In normal cells, however, SPOP is located in the nucleus and induces apoptosis. Here we show that a structure-based design and subsequent hit optimization yield small molecules that can inhibit the SPOP-substrate protein interaction and can suppress oncogenic SPOP-signaling pathways. These inhibitors kill human ccRCC cells that are dependent on oncogenic cytoplasmic SPOP. Notably, these inhibitors minimally affect the viability of other cells in which SPOP is not accumulated in the cytoplasm. Our findings validate the SPOP-substrate protein interaction as an attractive target specific to ccRCC that may yield novel drug discovery efforts.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27622336 DOI: 10.1016/j.ccell.2016.08.003
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743